Chronic Hyperpigmented Patches on the Legs

Article Type
Changed
Tue, 01/04/2022 - 10:43
Display Headline
Chronic Hyperpigmented Patches on the Legs

The Diagnosis: Drug-Induced Hyperpigmentation

Additional history provided by the patient’s caretaker elucidated an extensive list of medications including chlorpromazine and minocycline, among several others. The caretaker revealed that the patient began treatment for acne vulgaris 2 years prior; despite the acne resolving, therapy was not discontinued. The blue-gray and brown pigmentation on our patient’s shins likely was attributed to a medication he was taking.

Both chlorpromazine and minocycline, among many other medications, are known to cause abnormal pigmentation of the skin.1 Minocycline is a tetracycline antibiotic prescribed for acne and other inflammatory cutaneous conditions. It is highly lipophilic, allowing it to reach high drug concentrations in the skin and nail unit.2 Patients taking minocycline long term and at high doses are at greatest risk for pigment deposition.3,4

Minocycline-induced hyperpigmentation is classified into 3 types. Type I describes blue-black deposition of pigment in acne scars and areas of inflammation, typically on facial skin.1,5 Histologically, type I stains positive for Perls Prussian blue, indicating an increased deposition of iron as hemosiderin,1 which likely occurs because minocycline is thought to play a role in defective clearance of hemosiderin from the dermis of injured tissue.5 Type II hyperpigmentation presents as bluegray pigment on the lower legs and occasionally the arms.6,7 Type II stains positive for both Perls Prussian blue and Fontana-Masson, demonstrating hemosiderin and melanin, respectively.6 The third form of hyperpigmentation results in diffuse, dark brown to gray pigmentation with a predilection for sun-exposed areas.8 Histology of type III shows increased pigment in the basal portion of the epidermis and brown-black pigment in macrophages of the dermis. Type III stains positive for Fontana-Masson and negative for Perls Prussian blue. The etiology of hyperpigmentation has been suspected to be caused by minocycline stimulating melanin production and/or deposition of minocycline-melanin complexes in dermal macrophages after a certain drug level; this largely is seen in patients receiving 100 to 200 mg daily as early as 1 year into treatment.8

Chlorpromazine is a typical antipsychotic that causes abnormal skin pigmentation in sun-exposed areas due to increased melanogenesis.9 Similar to type III minocyclineinduced hyperpigmentation, a histologic specimen may stain positive for Fontana-Masson yet negative for Perls Prussian blue. Lal et al10 demonstrated complete resolution of abnormal skin pigmentation within 5 years after stopping chlorpromazine. In contrast, minocyclineinduced hyperpigmentation may be permanent in some cases. There is substantial clinical and histologic overlap for drug-induced hyperpigmentation etiologies; it would behoove the clinician to focus on the most common locations affected and the generalized coloration.

Treatment of minocycline-induced hyperpigmentation includes the use of Q-switched lasers, specifically Q-switched ruby and Q-switched alexandrite.11 The use of the Q-switched Nd:YAG laser appears to be ineffective at clearing minocycline-induced pigmentation.7,11 In our patient, minocycline was discontinued immediately. Due to the patient’s critical condition, he deferred all other therapy. Erythema dyschromicum perstans, also referred to as ashy dermatosis, is an idiopathic form of hyperpigmentation.12 Lesions start as blue-gray to ashy gray macules, occasionally surrounded by a slightly erythematous, raised border.

Erythema dyschromicum perstans typically presents on the trunk, face, and arms of patients with Fitzpatrick skin types III and IV; it is considered a variant of lichen planus actinicus.12 Histologically, erythema dyschromicum perstans may mimic lichen planus pigmentosus (LPP); however, subtle differences exist to distinguish the 2 conditions. Erythema dyschromicum perstans demonstrates a mild lichenoid infiltrate, focal basal vacuolization at the dermoepidermal junction, and melanophage deposition.13 In contrast, LPP demonstrates pigmentary incontinence and a more severe inflammatory infiltrate. A perifollicular infiltrate and fibrosis also can be seen in LPP, which may explain the frontal fibrosing alopecia that often precedes LPP.13

Addison disease, also known as primary adrenal insufficiency, can cause diffuse hyperpigmentation in the skin, mucosae, and nail beds. The pigmentation is prominent in regions of naturally increased pigmentation, such as the flexural surfaces and intertriginous areas.14 Patients with adrenal insufficiency will have accompanying weight loss, hypotension, and fatigue, among other symptoms related to deficiency of cortisol and aldosterone. Skin biopsy shows acanthosis, hyperkeratosis, focal parakeratosis, spongiosis, superficial perivascular lymphocytic infiltrate, basal melanin deposition, and superficial dermal macrophages.15

Confluent and reticulated papillomatosis is an uncommon dermatosis that presents with multiple hyperpigmented macules and papules that coalesce to form patches and plaques centrally with reticulation in the periphery.16 Confluent and reticulated papillomatosis commonly presents on the upper trunk, axillae, and neck, though involvement can include flexural surfaces as well as the lower trunk and legs.16,17 Biopsy demonstrates undulating hyperkeratosis, papillomatosis, acanthosis, and negative fungal staining.16

Pretibial myxedema most commonly is associated with Graves disease and presents as well-defined thickening and induration with overlying pink or purple-brown papules in the pretibial region.18 An acral surface and mucin deposition within the entire dermis may be appreciated on histology with staining for colloidal iron or Alcian blue.

References
  1. Fenske NA, Millns JL, Greer KE. Minocycline-induced pigmentation at sites of cutaneous inflammation. JAMA. 1980;244:1103-1106. doi:10.1001/jama.1980.03310100021021
  2. Snodgrass A, Motaparthi K. Systemic antibacterial agents. In: Wolverton SE, Wu JJ, eds. Comprehensive Dermatologic Drug Therapy. 4th ed. Elsevier; 2020:69-98.
  3. Eisen D, Hakim MD. Minocycline-induced pigmentation. incidence, prevention and management. Drug Saf. 1998;18:431-440. doi:10.2165/00002018-199818060-00004
  4. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol. 1996;134:693-695. doi:10.1111/j.1365-2133.1996.tb06972.x
  5. Basler RS, Kohnen PW. Localized hemosiderosis as a sequela of acne. Arch Dermatol. 1978;114:1695-1697.
  6. Ridgway HA, Sonnex TS, Kennedy CT, et al. Hyperpigmentation associated with oral minocycline. Br J Dermatol. 1982;107:95-102. doi:10.1111/j.1365-2133.1982.tb00296.x
  7. Nisar MS, Iyer K, Brodell RT, et al. Minocycline-induced hyperpigmentation: comparison of 3 Q-switched lasers to reverse its effects. Clin Cosmet Investig Dermatol. 2013;6:159-162. doi:10.2147/CCID.S42166
  8. Simons JJ, Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol. 1980;3:244-247. doi:10.1016/s0190 -9622(80)80186-1
  9. Perry TL, Culling CF, Berry K, et al. 7-Hydroxychlorpromazine: potential toxic drug metabolite in psychiatric patients. Science. 1964;146:81-83. doi:10.1126/science.146.3640.81
  10. Lal S, Bloom D, Silver B, et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci. 1993;18:173-177.
  11. Tsao H, Busam K, Barnhill RL, et al. Treatment of minocycline-induced hyperpigmentation with the Q-switched ruby laser. Arch Dermatol. 1996;132:1250-1251.
  12. Knox JM, Dodge BG, Freeman RG. Erythema dyschromicum perstans. Arch Dermatol. 1968;97:262-272. doi:10.1001 /archderm.1968.01610090034006
  13. Rutnin S, Udompanich S, Pratumchart N, et al. Ashy dermatosis and lichen planus pigmentosus: the histopathological differences. Biomed Res Int. 2019;2019:5829185. doi:10.1155/2019/5829185
  14. Montgomery H, O’Leary PA. Pigmentation of the skin in Addison’s disease, acanthosis nigricans and hemochromatosis. Arch Derm Syphilol. 1930;21:970-984. doi:10.1001 /archderm.1930.01440120072005
  15. Fernandez-Flores A, Cassarino DS. Histopathologic findings of cutaneous hyperpigmentation in Addison disease and immunostain of the melanocytic population. Am J Dermatopathol. 2017;39:924-927. doi:10.1097/DAD.0000000000000937
  16. Davis MD, Weenig RH, Camilleri MJ. Confluent and reticulate papillomatosis (Gougerot-Carteaud syndrome): a minocycline-responsive dermatosis without evidence for yeast in pathogenesis. a study of 39 patients and a proposal of diagnostic criteria. Br J Dermatol. 2006;154:287-293. doi:10.1111/j.1365-2133.2005.06955.x
  17. Jo S, Park HS, Cho S, et al. Updated diagnosis criteria for confluent and reticulated papillomatosis: a case report. Ann Dermatol. 2014; 26:409-410. doi:10.5021/ad.2014.26.3.409
  18. Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017;6:300-312. doi:10.21037 /tp.2017.09.08
Article PDF
Author and Disclosure Information

Dr. Kolodziejczyk is from Rocky Vista University College of Osteopathic Medicine, Parker, Colorado. Drs. Fronek and Esguerra are from the Department of Dermatology, HCA Healthcare/USF Morsani College of Medicine, Largo Medical Center Program, Florida.

The authors report no conflict of interest.

Correspondence: Lisa F. Fronek, DO (lisa.fronek@hcahealthcare.com).

Issue
cutis - 108(3)
Publications
Topics
Page Number
e22-e24
Sections
Author and Disclosure Information

Dr. Kolodziejczyk is from Rocky Vista University College of Osteopathic Medicine, Parker, Colorado. Drs. Fronek and Esguerra are from the Department of Dermatology, HCA Healthcare/USF Morsani College of Medicine, Largo Medical Center Program, Florida.

The authors report no conflict of interest.

Correspondence: Lisa F. Fronek, DO (lisa.fronek@hcahealthcare.com).

Author and Disclosure Information

Dr. Kolodziejczyk is from Rocky Vista University College of Osteopathic Medicine, Parker, Colorado. Drs. Fronek and Esguerra are from the Department of Dermatology, HCA Healthcare/USF Morsani College of Medicine, Largo Medical Center Program, Florida.

The authors report no conflict of interest.

Correspondence: Lisa F. Fronek, DO (lisa.fronek@hcahealthcare.com).

Article PDF
Article PDF
Related Articles

The Diagnosis: Drug-Induced Hyperpigmentation

Additional history provided by the patient’s caretaker elucidated an extensive list of medications including chlorpromazine and minocycline, among several others. The caretaker revealed that the patient began treatment for acne vulgaris 2 years prior; despite the acne resolving, therapy was not discontinued. The blue-gray and brown pigmentation on our patient’s shins likely was attributed to a medication he was taking.

Both chlorpromazine and minocycline, among many other medications, are known to cause abnormal pigmentation of the skin.1 Minocycline is a tetracycline antibiotic prescribed for acne and other inflammatory cutaneous conditions. It is highly lipophilic, allowing it to reach high drug concentrations in the skin and nail unit.2 Patients taking minocycline long term and at high doses are at greatest risk for pigment deposition.3,4

Minocycline-induced hyperpigmentation is classified into 3 types. Type I describes blue-black deposition of pigment in acne scars and areas of inflammation, typically on facial skin.1,5 Histologically, type I stains positive for Perls Prussian blue, indicating an increased deposition of iron as hemosiderin,1 which likely occurs because minocycline is thought to play a role in defective clearance of hemosiderin from the dermis of injured tissue.5 Type II hyperpigmentation presents as bluegray pigment on the lower legs and occasionally the arms.6,7 Type II stains positive for both Perls Prussian blue and Fontana-Masson, demonstrating hemosiderin and melanin, respectively.6 The third form of hyperpigmentation results in diffuse, dark brown to gray pigmentation with a predilection for sun-exposed areas.8 Histology of type III shows increased pigment in the basal portion of the epidermis and brown-black pigment in macrophages of the dermis. Type III stains positive for Fontana-Masson and negative for Perls Prussian blue. The etiology of hyperpigmentation has been suspected to be caused by minocycline stimulating melanin production and/or deposition of minocycline-melanin complexes in dermal macrophages after a certain drug level; this largely is seen in patients receiving 100 to 200 mg daily as early as 1 year into treatment.8

Chlorpromazine is a typical antipsychotic that causes abnormal skin pigmentation in sun-exposed areas due to increased melanogenesis.9 Similar to type III minocyclineinduced hyperpigmentation, a histologic specimen may stain positive for Fontana-Masson yet negative for Perls Prussian blue. Lal et al10 demonstrated complete resolution of abnormal skin pigmentation within 5 years after stopping chlorpromazine. In contrast, minocyclineinduced hyperpigmentation may be permanent in some cases. There is substantial clinical and histologic overlap for drug-induced hyperpigmentation etiologies; it would behoove the clinician to focus on the most common locations affected and the generalized coloration.

Treatment of minocycline-induced hyperpigmentation includes the use of Q-switched lasers, specifically Q-switched ruby and Q-switched alexandrite.11 The use of the Q-switched Nd:YAG laser appears to be ineffective at clearing minocycline-induced pigmentation.7,11 In our patient, minocycline was discontinued immediately. Due to the patient’s critical condition, he deferred all other therapy. Erythema dyschromicum perstans, also referred to as ashy dermatosis, is an idiopathic form of hyperpigmentation.12 Lesions start as blue-gray to ashy gray macules, occasionally surrounded by a slightly erythematous, raised border.

Erythema dyschromicum perstans typically presents on the trunk, face, and arms of patients with Fitzpatrick skin types III and IV; it is considered a variant of lichen planus actinicus.12 Histologically, erythema dyschromicum perstans may mimic lichen planus pigmentosus (LPP); however, subtle differences exist to distinguish the 2 conditions. Erythema dyschromicum perstans demonstrates a mild lichenoid infiltrate, focal basal vacuolization at the dermoepidermal junction, and melanophage deposition.13 In contrast, LPP demonstrates pigmentary incontinence and a more severe inflammatory infiltrate. A perifollicular infiltrate and fibrosis also can be seen in LPP, which may explain the frontal fibrosing alopecia that often precedes LPP.13

Addison disease, also known as primary adrenal insufficiency, can cause diffuse hyperpigmentation in the skin, mucosae, and nail beds. The pigmentation is prominent in regions of naturally increased pigmentation, such as the flexural surfaces and intertriginous areas.14 Patients with adrenal insufficiency will have accompanying weight loss, hypotension, and fatigue, among other symptoms related to deficiency of cortisol and aldosterone. Skin biopsy shows acanthosis, hyperkeratosis, focal parakeratosis, spongiosis, superficial perivascular lymphocytic infiltrate, basal melanin deposition, and superficial dermal macrophages.15

Confluent and reticulated papillomatosis is an uncommon dermatosis that presents with multiple hyperpigmented macules and papules that coalesce to form patches and plaques centrally with reticulation in the periphery.16 Confluent and reticulated papillomatosis commonly presents on the upper trunk, axillae, and neck, though involvement can include flexural surfaces as well as the lower trunk and legs.16,17 Biopsy demonstrates undulating hyperkeratosis, papillomatosis, acanthosis, and negative fungal staining.16

Pretibial myxedema most commonly is associated with Graves disease and presents as well-defined thickening and induration with overlying pink or purple-brown papules in the pretibial region.18 An acral surface and mucin deposition within the entire dermis may be appreciated on histology with staining for colloidal iron or Alcian blue.

The Diagnosis: Drug-Induced Hyperpigmentation

Additional history provided by the patient’s caretaker elucidated an extensive list of medications including chlorpromazine and minocycline, among several others. The caretaker revealed that the patient began treatment for acne vulgaris 2 years prior; despite the acne resolving, therapy was not discontinued. The blue-gray and brown pigmentation on our patient’s shins likely was attributed to a medication he was taking.

Both chlorpromazine and minocycline, among many other medications, are known to cause abnormal pigmentation of the skin.1 Minocycline is a tetracycline antibiotic prescribed for acne and other inflammatory cutaneous conditions. It is highly lipophilic, allowing it to reach high drug concentrations in the skin and nail unit.2 Patients taking minocycline long term and at high doses are at greatest risk for pigment deposition.3,4

Minocycline-induced hyperpigmentation is classified into 3 types. Type I describes blue-black deposition of pigment in acne scars and areas of inflammation, typically on facial skin.1,5 Histologically, type I stains positive for Perls Prussian blue, indicating an increased deposition of iron as hemosiderin,1 which likely occurs because minocycline is thought to play a role in defective clearance of hemosiderin from the dermis of injured tissue.5 Type II hyperpigmentation presents as bluegray pigment on the lower legs and occasionally the arms.6,7 Type II stains positive for both Perls Prussian blue and Fontana-Masson, demonstrating hemosiderin and melanin, respectively.6 The third form of hyperpigmentation results in diffuse, dark brown to gray pigmentation with a predilection for sun-exposed areas.8 Histology of type III shows increased pigment in the basal portion of the epidermis and brown-black pigment in macrophages of the dermis. Type III stains positive for Fontana-Masson and negative for Perls Prussian blue. The etiology of hyperpigmentation has been suspected to be caused by minocycline stimulating melanin production and/or deposition of minocycline-melanin complexes in dermal macrophages after a certain drug level; this largely is seen in patients receiving 100 to 200 mg daily as early as 1 year into treatment.8

Chlorpromazine is a typical antipsychotic that causes abnormal skin pigmentation in sun-exposed areas due to increased melanogenesis.9 Similar to type III minocyclineinduced hyperpigmentation, a histologic specimen may stain positive for Fontana-Masson yet negative for Perls Prussian blue. Lal et al10 demonstrated complete resolution of abnormal skin pigmentation within 5 years after stopping chlorpromazine. In contrast, minocyclineinduced hyperpigmentation may be permanent in some cases. There is substantial clinical and histologic overlap for drug-induced hyperpigmentation etiologies; it would behoove the clinician to focus on the most common locations affected and the generalized coloration.

Treatment of minocycline-induced hyperpigmentation includes the use of Q-switched lasers, specifically Q-switched ruby and Q-switched alexandrite.11 The use of the Q-switched Nd:YAG laser appears to be ineffective at clearing minocycline-induced pigmentation.7,11 In our patient, minocycline was discontinued immediately. Due to the patient’s critical condition, he deferred all other therapy. Erythema dyschromicum perstans, also referred to as ashy dermatosis, is an idiopathic form of hyperpigmentation.12 Lesions start as blue-gray to ashy gray macules, occasionally surrounded by a slightly erythematous, raised border.

Erythema dyschromicum perstans typically presents on the trunk, face, and arms of patients with Fitzpatrick skin types III and IV; it is considered a variant of lichen planus actinicus.12 Histologically, erythema dyschromicum perstans may mimic lichen planus pigmentosus (LPP); however, subtle differences exist to distinguish the 2 conditions. Erythema dyschromicum perstans demonstrates a mild lichenoid infiltrate, focal basal vacuolization at the dermoepidermal junction, and melanophage deposition.13 In contrast, LPP demonstrates pigmentary incontinence and a more severe inflammatory infiltrate. A perifollicular infiltrate and fibrosis also can be seen in LPP, which may explain the frontal fibrosing alopecia that often precedes LPP.13

Addison disease, also known as primary adrenal insufficiency, can cause diffuse hyperpigmentation in the skin, mucosae, and nail beds. The pigmentation is prominent in regions of naturally increased pigmentation, such as the flexural surfaces and intertriginous areas.14 Patients with adrenal insufficiency will have accompanying weight loss, hypotension, and fatigue, among other symptoms related to deficiency of cortisol and aldosterone. Skin biopsy shows acanthosis, hyperkeratosis, focal parakeratosis, spongiosis, superficial perivascular lymphocytic infiltrate, basal melanin deposition, and superficial dermal macrophages.15

Confluent and reticulated papillomatosis is an uncommon dermatosis that presents with multiple hyperpigmented macules and papules that coalesce to form patches and plaques centrally with reticulation in the periphery.16 Confluent and reticulated papillomatosis commonly presents on the upper trunk, axillae, and neck, though involvement can include flexural surfaces as well as the lower trunk and legs.16,17 Biopsy demonstrates undulating hyperkeratosis, papillomatosis, acanthosis, and negative fungal staining.16

Pretibial myxedema most commonly is associated with Graves disease and presents as well-defined thickening and induration with overlying pink or purple-brown papules in the pretibial region.18 An acral surface and mucin deposition within the entire dermis may be appreciated on histology with staining for colloidal iron or Alcian blue.

References
  1. Fenske NA, Millns JL, Greer KE. Minocycline-induced pigmentation at sites of cutaneous inflammation. JAMA. 1980;244:1103-1106. doi:10.1001/jama.1980.03310100021021
  2. Snodgrass A, Motaparthi K. Systemic antibacterial agents. In: Wolverton SE, Wu JJ, eds. Comprehensive Dermatologic Drug Therapy. 4th ed. Elsevier; 2020:69-98.
  3. Eisen D, Hakim MD. Minocycline-induced pigmentation. incidence, prevention and management. Drug Saf. 1998;18:431-440. doi:10.2165/00002018-199818060-00004
  4. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol. 1996;134:693-695. doi:10.1111/j.1365-2133.1996.tb06972.x
  5. Basler RS, Kohnen PW. Localized hemosiderosis as a sequela of acne. Arch Dermatol. 1978;114:1695-1697.
  6. Ridgway HA, Sonnex TS, Kennedy CT, et al. Hyperpigmentation associated with oral minocycline. Br J Dermatol. 1982;107:95-102. doi:10.1111/j.1365-2133.1982.tb00296.x
  7. Nisar MS, Iyer K, Brodell RT, et al. Minocycline-induced hyperpigmentation: comparison of 3 Q-switched lasers to reverse its effects. Clin Cosmet Investig Dermatol. 2013;6:159-162. doi:10.2147/CCID.S42166
  8. Simons JJ, Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol. 1980;3:244-247. doi:10.1016/s0190 -9622(80)80186-1
  9. Perry TL, Culling CF, Berry K, et al. 7-Hydroxychlorpromazine: potential toxic drug metabolite in psychiatric patients. Science. 1964;146:81-83. doi:10.1126/science.146.3640.81
  10. Lal S, Bloom D, Silver B, et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci. 1993;18:173-177.
  11. Tsao H, Busam K, Barnhill RL, et al. Treatment of minocycline-induced hyperpigmentation with the Q-switched ruby laser. Arch Dermatol. 1996;132:1250-1251.
  12. Knox JM, Dodge BG, Freeman RG. Erythema dyschromicum perstans. Arch Dermatol. 1968;97:262-272. doi:10.1001 /archderm.1968.01610090034006
  13. Rutnin S, Udompanich S, Pratumchart N, et al. Ashy dermatosis and lichen planus pigmentosus: the histopathological differences. Biomed Res Int. 2019;2019:5829185. doi:10.1155/2019/5829185
  14. Montgomery H, O’Leary PA. Pigmentation of the skin in Addison’s disease, acanthosis nigricans and hemochromatosis. Arch Derm Syphilol. 1930;21:970-984. doi:10.1001 /archderm.1930.01440120072005
  15. Fernandez-Flores A, Cassarino DS. Histopathologic findings of cutaneous hyperpigmentation in Addison disease and immunostain of the melanocytic population. Am J Dermatopathol. 2017;39:924-927. doi:10.1097/DAD.0000000000000937
  16. Davis MD, Weenig RH, Camilleri MJ. Confluent and reticulate papillomatosis (Gougerot-Carteaud syndrome): a minocycline-responsive dermatosis without evidence for yeast in pathogenesis. a study of 39 patients and a proposal of diagnostic criteria. Br J Dermatol. 2006;154:287-293. doi:10.1111/j.1365-2133.2005.06955.x
  17. Jo S, Park HS, Cho S, et al. Updated diagnosis criteria for confluent and reticulated papillomatosis: a case report. Ann Dermatol. 2014; 26:409-410. doi:10.5021/ad.2014.26.3.409
  18. Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017;6:300-312. doi:10.21037 /tp.2017.09.08
References
  1. Fenske NA, Millns JL, Greer KE. Minocycline-induced pigmentation at sites of cutaneous inflammation. JAMA. 1980;244:1103-1106. doi:10.1001/jama.1980.03310100021021
  2. Snodgrass A, Motaparthi K. Systemic antibacterial agents. In: Wolverton SE, Wu JJ, eds. Comprehensive Dermatologic Drug Therapy. 4th ed. Elsevier; 2020:69-98.
  3. Eisen D, Hakim MD. Minocycline-induced pigmentation. incidence, prevention and management. Drug Saf. 1998;18:431-440. doi:10.2165/00002018-199818060-00004
  4. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol. 1996;134:693-695. doi:10.1111/j.1365-2133.1996.tb06972.x
  5. Basler RS, Kohnen PW. Localized hemosiderosis as a sequela of acne. Arch Dermatol. 1978;114:1695-1697.
  6. Ridgway HA, Sonnex TS, Kennedy CT, et al. Hyperpigmentation associated with oral minocycline. Br J Dermatol. 1982;107:95-102. doi:10.1111/j.1365-2133.1982.tb00296.x
  7. Nisar MS, Iyer K, Brodell RT, et al. Minocycline-induced hyperpigmentation: comparison of 3 Q-switched lasers to reverse its effects. Clin Cosmet Investig Dermatol. 2013;6:159-162. doi:10.2147/CCID.S42166
  8. Simons JJ, Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol. 1980;3:244-247. doi:10.1016/s0190 -9622(80)80186-1
  9. Perry TL, Culling CF, Berry K, et al. 7-Hydroxychlorpromazine: potential toxic drug metabolite in psychiatric patients. Science. 1964;146:81-83. doi:10.1126/science.146.3640.81
  10. Lal S, Bloom D, Silver B, et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci. 1993;18:173-177.
  11. Tsao H, Busam K, Barnhill RL, et al. Treatment of minocycline-induced hyperpigmentation with the Q-switched ruby laser. Arch Dermatol. 1996;132:1250-1251.
  12. Knox JM, Dodge BG, Freeman RG. Erythema dyschromicum perstans. Arch Dermatol. 1968;97:262-272. doi:10.1001 /archderm.1968.01610090034006
  13. Rutnin S, Udompanich S, Pratumchart N, et al. Ashy dermatosis and lichen planus pigmentosus: the histopathological differences. Biomed Res Int. 2019;2019:5829185. doi:10.1155/2019/5829185
  14. Montgomery H, O’Leary PA. Pigmentation of the skin in Addison’s disease, acanthosis nigricans and hemochromatosis. Arch Derm Syphilol. 1930;21:970-984. doi:10.1001 /archderm.1930.01440120072005
  15. Fernandez-Flores A, Cassarino DS. Histopathologic findings of cutaneous hyperpigmentation in Addison disease and immunostain of the melanocytic population. Am J Dermatopathol. 2017;39:924-927. doi:10.1097/DAD.0000000000000937
  16. Davis MD, Weenig RH, Camilleri MJ. Confluent and reticulate papillomatosis (Gougerot-Carteaud syndrome): a minocycline-responsive dermatosis without evidence for yeast in pathogenesis. a study of 39 patients and a proposal of diagnostic criteria. Br J Dermatol. 2006;154:287-293. doi:10.1111/j.1365-2133.2005.06955.x
  17. Jo S, Park HS, Cho S, et al. Updated diagnosis criteria for confluent and reticulated papillomatosis: a case report. Ann Dermatol. 2014; 26:409-410. doi:10.5021/ad.2014.26.3.409
  18. Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017;6:300-312. doi:10.21037 /tp.2017.09.08
Issue
cutis - 108(3)
Issue
cutis - 108(3)
Page Number
e22-e24
Page Number
e22-e24
Publications
Publications
Topics
Article Type
Display Headline
Chronic Hyperpigmented Patches on the Legs
Display Headline
Chronic Hyperpigmented Patches on the Legs
Sections
Questionnaire Body

A 37-year-old man with a history of cerebral palsy, bipolar disorder, and impulse control disorder presented to the emergency department with breathing difficulty and worsening malaise. The patient subsequently was intubated due to hypoxic respiratory failure and was found to be positive for SARS-CoV-2. He was admitted to the intensive care unit, and dermatology was consulted due to concern that the cutaneous findings were demonstrative of a vasculitic process. Physical examination revealed diffuse, symmetric, dark brown to blue-gray macules coalescing into patches on the anterior tibia (top) and covering the entire lower leg (bottom). The patches were mottled and did not blanch with pressure. According to the patient’s caretaker, the leg hyperpigmentation had been present for 2 years.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 10/06/2021 - 07:45
Un-Gate On Date
Wed, 10/06/2021 - 07:45
Use ProPublica
CFC Schedule Remove Status
Wed, 10/06/2021 - 07:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Primary Cutaneous Apocrine Carcinoma Arising Within a Nevus Sebaceus

Article Type
Changed
Thu, 01/10/2019 - 13:54

Nevus sebaceus (NS) is a benign hair follicle neoplasm present in approximately 1.3% of the population, typically involving the scalp, neck, or face.1 These lesions usually are present at birth or identified soon after, during the first year. They present as a yellowish hairless patch or plaque but can develop a more papillomatous appearance, especially after puberty. Historically, the concern with NS was its tendency to transform into basal cell carcinoma (BCC), which prompted surgical excision of the lesion during childhood. This theory has been discounted more recently, as further research has suggested that what was once thought to be BCC may have been confused with the similarly appearing trichoblastoma; however, malignant transformation of NS does still occur, with BCC still being the most common.2 We present the case of a long-standing NS with rare transformation to apocrine carcinoma.

Case Report

A 76-year-old woman presented with several new lesions within a previously diagnosed NS. She reported having the large plaque for as long as she could recall but reported that several new growths developed within the plaque over the last 2 months, slowly increasing in size. She reported a prior biopsy within the growth several years prior, which she described as an irritated seborrheic keratosis.

Physical examination demonstrated 4 distinct lesions within the flesh-colored, verrucous plaque located on the left side of the temporal scalp (Figure 1). The first lesion was a 2.5-cm pearly, pink, exophytic tumor (labeled as A in Figure 1). The next 2 lesions were brown, pedunculated, verrucous papules (labeled as B and C in Figure 1). The last lesion was a purple papule (labeled as D in Figure 1). Four shave biopsies were performed for histologic analysis of the lesions. Lesions B, C, and D were consistent with trichoblastomas, as pathology showed basaloid epithelial tumors that displayed primitive follicular structures, areas of stromal induction, and some pigmentation. Lesion A, originally thought to be suspicious for a BCC, was determined to be a primary cutaneous apocrine adenocarcinoma upon pathologic review. The pathology showed a dermal tumor displaying solid and tubular areas with decapitation secretion. Nuclear pleomorphism and mitoses were present (Figure 2), and staining for carcinoembryonic antigen was positive (Figure 3). Immunoreactivity with epithelial membrane antigen and cytokeratin 7 was noted as well as focal positivity for mammaglobin. Primary apocrine carcinoma was favored over metastatic carcinoma due to the location of the lesion within an NS along with a negative history of internal malignancy. Dermatopathology recommended complete removal of all lesions within the NS.

Figure1
Figure 1. Verrucous plaque and 4 distinct neoplasms (labeled A–D) on the left side of the temporal scalp.

Figure2
Figure 2. Apocrine carcinoma histopathology demonstrating solid and tubular areas with decapitation secretion (A)(H&E). On high power, marked nuclear pleomorphism and increased mitotic activity were observed (B)(H&E).

Figure3
Figure 3. Apocrine carcinoma demonstrating carcinoembryonic antigen staining positivity.


Upon discussing biopsy results and recommendations with our patient, she agreed to undergo excision with intraoperative pathology by a plastic surgeon within our practice to ensure clear margins. The surgical defect following excision was sizeable and closed utilizing a rhomboid flap, full-thickness skin graft, and a split-thickness skin graft. At surgical follow-up, she was doing well and there have been no signs of local recurrence for 10 months since excision.

 

 

Comment

Presentation
Nevus sebaceus is the most common adnexal tumor and is classified as a benign congenital hair follicle tumor that is located most commonly on the scalp but also occurs on the face and neck.1 The lesions usually are present at birth but also can develop during the first year of life.2 Diagnosis may be later, during adolescence, when patients seek medical attention during the lesion’s rapid growth phase.1 Nevus sebaceus also is known as an organoid nevus because it may contain all components of the skin. It was originally identified by Jadassohn in 1895.3 It presents as a yellowish, smooth, hairless patch or plaque in prepubertal patients. During adolescence, the lesion typically becomes more yellowish, as well as papillomatous, scaly, or warty. The reported incidence of NS is 0.05% to 1% in dermatology patients.2

Differential
Nevus sebaceus also is a component of several syndromes that should be kept in mind, including Schimmelpenning-Feuerstein-Mims syndrome, which presents with neurologic, skeletal, genitourinary, cardiovascular, and ophthalmic disorders, in addition to cutaneous features. Others include phacomatosis pigmentokeratotica, didmyosis aplasticosebacea, SCALP syndrome (sebaceus nevus, central nervous system malformations, aplasia cutis congenita, limbal dermoid, and pigmented nevus), and more.4,5

Etiology
The etiology of NS has not been completely determined. One study that evaluated 44 NS tissue samples suggested the presence of human papillomavirus (HPV) in NS formation, finding that 82% of NS lesions studied contained HPV DNA. From these results, Carlson et al6 suggested a possible maternal transmission of HPV and infection of ectodermal cells as a potential cause of NS; however, this hypothesis was soon challenged by a study that showed a complete absence of HPV in 16 samples via histological evaluation and polymerase chain reaction for a broad range of HPV types.7 There were investigations into a patched (PTCH) deletion as the cause of NS and thus explained the historically high rate of secondary BCC.8 Further studies showed no mutations at the PTCH locus in trichoblastomas or other tumors arising from NS.9,10

More recent studies have recognized HRAS and KRAS mutations as a causative factor in NS.11 Nevus sebaceus belongs to a group of syndromes resulting from lethal mutations that survive via mosaicism. Nevus sebaceus is caused by postzygotic HRAS or KRAS mutations and is known as a mosaic RASopathy.12 In fact, there is growing evidence to suggest that other nevoid proliferations including keratinocytic epidermal nevi and melanocytic nevi also fall into the spectrum of mosaic RASopathies.13

Staging
There are 3 clinical stages of NS, originally described by Mehregan and Pinkus.14 In stage I (historically known as the infantile stage), the lesion presents as a yellow to pink, smooth, hairless patch. Histologic features include immature hair follicles and hypoplastic sebaceous glands. In stage II (also known as the puberty stage), the lesion becomes more pronounced. Firmer plaques can develop with hyperkeratosis. Hormonal changes cause sebaceous glands to develop, accompanied by epidermal hyperplasia and maturation of apocrine glands. Stage III (the tumoral stage) is a period that various neoplasms have the highest likelihood of occurring. Nevus sebaceus in an adolescent or adult demonstrates mature adnexal structures and greater epidermal hyperplasia.2,4,15

Malignancy
By virtue of these stages of NS development, malignant transformation is expected most often during stage III. However, cases have been reported of malignant tumor development in NS in children before puberty. Two case reports described a 7-year-old boy and a 10-year-old boy diagnosed with a BCC arising from an NS.16,17 However, secondary BCC formation before 16 years of age is rare. Basal cell carcinoma arising from an NS has been commonly reported and is the most common malignant neoplasm in NS (1.1%).2,3 However, the most common neoplasm overall is trichoblastoma (7.4%). The second most common tumor was syringocystadenoma papilliferum, occurring in approximately 5.2% of NS cases. The neoplasm rate in NS was found to be proportional to the patient age.2,18 Multiple studies have shown the overall rate of secondary neoplasms in NS to be 13% to 21.4%, with malignant tumors composing 0.8% to 2.5%.2,15,19 Other neoplasms that have been reported include keratoacanthoma, trichilemmoma, sebaceoma, nevocellular nevus, squamous cell carcinoma, adnexal carcinoma, apocrine adenocarcinoma, and malignant melanoma.19-21

It is argued that the reported rate of BCC formation is overestimated, as prior studies incorrectly labeled trichoblastomas as BCCs. In fact, the largest studies of NS from the 1990s revealed lower rates of malignant secondary tumors than previously determined.4

The identification of apocrine adenocarcinoma tumors arising from NS is exceedingly rare. A study performed by Cribier et al19 in 2000 retrospectively analyzed 596 cases of excised NS from 1932 to 1998. No apocrine carcinomas were reported in this study.19 Approximately 12 cases have been previously reported throughout the literature.20-26 Apocrine carcinomas occur most frequently in apocrine-rich areas such as the axillae, external ears, eyelids, and anogenital area. However, in the cases with apocrine carcinomas that developed from NS, the carcinomas have been located almost exclusively on the scalp.23

Histopathology
Histopathologic examination reveals considerable variation in morphology, and an underlying pattern has been difficult to recognize. Unfortunately, some authors have concluded that the diagnosis of apocrine carcinoma is relatively subjective.26 Robson et al26 identified 3 general architectural patterns: tubular, tubulopapillary, and solid. Tubular structures consisted of glands and ducts lined by a single or multilayered epithelium. Tubulopapillary architecture was characterized by epithelium forming papillary folds without a fibrovascular core. The solid morphology showed sheets of cells with limited ductal or tubular formation.26 The most specific criteria of these apocrine carcinomas are identification of decapitation secretion, periodic acid–Schiff–positive diastase-resistant material present in the cells or lumen, and positive immunostaining for gross cystic disease fluid protein-15.27

Robson et al26 reported estrogen receptor positivity and androgen receptor positivity in 62% and 64% of 24 primary apocrine carcinoma cases, respectively. However, whether these markers are as common in NS-related apocrine carcinomas has yet to be noted in the literature. One study reports a case of apocrine carcinoma from NS with positive staining for human epidermal growth factor-2, a cell membrane receptor tyrosine kinase commonly investigated in breast cancers and extramammary Paget disease.22

These apocrine carcinomas do have the potential for lymphatic metastasis, as seen with multiple studies. Domingo and Helwig21 identified regional lymph node metastasis in 2 of its 4 apocrine carcinoma patients. Robson et al26 reported lymphovascular invasion in 4 cases and perineural invasion in 2 of 24 patients studied. However, even in the context of recurrence and regional metastasis, the prognosis was good and seldom fatal.26

Treatment
The most effective treatment of NS is excision of dermal and epidermal components. Excision should be completed with a minimum of 2- to 3-mm margins and full thickness down to the underlying supporting fat.28 Historically, the practice of prophylactic excision of NS was supported by the potential for malignant transformation; however, early excision of NS may be less reasonable in light of these more recent studies showing lower incidence of BCC (0.8%), replaced by benign trichoblastomas.19 In the case of apocrine carcinoma development, excision is undoubtedly recommended, with unclear recommendations regarding further evaluation for metastasis.

Excision also may be favored for cosmetic purposes, given the visible regions where NS tends to develop. Chepla and Gosain29 argued that surgical intervention should be based on other factors such as location on the scalp, alopecia, and other issues affecting appearance and monitoring rather than incidence of malignant transformation. Close monitoring and biopsy of suspicious areas is a more conservative option.

Other therapies include CO2 laser, as demonstrated by Kiedrowicz et al,30 on linear NS in a patient with Schimmelpenning-Feuerstein-Mims syndrome.31 However, this approach is palliative and not effective in removing the entire lesion. Electrodesiccation and curettage and dermabrasion also are not good options for the same reason.4

Occurrence in Children
Nevus sebaceus in children, accompanied by other findings suggestive of epidermal nevus syndromes, should prompt further investigation. Schimmelpenning-Feuerstein-Mims syndrome includes major neurological abnormalities including hemimegalencephaly and seizures.32

Conclusion

Apocrine carcinomas are malignant neoplasms that may rarely arise within an NS. Their clinical identification is difficult and requires histopathologic evaluation. Upon recognition, prompt excision with tumor-free margins is recommended. As a rare entity, little data is available regarding its metastatic potential or overall survival rates. Further investigation is clearly necessary as new cases arise.

References
  1. Kamyab-Hesari K, Balochi K, Afshar N, et al. Clinicopathological study of 1016 consecutive adnexal skin tumors. Acta Med Iran. 2013;51:879-885.
  2. Idriss MH, Elston DM. Secondary neoplasms associated with nevus sebaceus of Jadassohn: a study of 707 cases. J Am Acad Dermatol. 2014;70:332-337.
  3. Ball EA, Hussain M, Moss AL. Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol. 2005;30:259-260.
  4. Moody MN, Landau JM, Goldberg LH. Nevus sebaceous revisited. Pediatr Dermatol. 2012;29:15-23.
  5. Happle R. The group of epidermal nevus syndromes part I. well defined phenotypes. J Am Acad Dermatol. 2010;63:1-22; quiz 23-24.
  6. Carlson JA, Cribier B, Nuovo G, et al. Epidermodysplasia verruciformis-associated and genital-mucosal high-risk human papillomavirus DNA are prevalent in nevus sebaceus of Jadassohn. J Am Acad Dermatol. 2008;59:279-294.
  7. Kim D, Benjamin LT, Sahoo MK, et al. Human papilloma virus is not prevalent in nevus sebaceus [published online November 14, 2013]. Pediatr Dermatol. 2014;31:326-330.
  8. Xin H, Matt D, Qin JZ, et al. The sebaceous nevus: a nevus with deletions of the PTCH gene. Cancer Res. 1999;59:1834-1836.
  9. Hafner C, Schmiemann V, Ruetten A, et al. PTCH mutations are not mainly involved in the pathogenesis of sporadic trichoblastomas. Hum Pathol. 2007;38:1496-1500.
  10. Takata M, Tojo M, Hatta N, et al. No evidence of deregulated patched-hedgehog signaling pathway in trichoblastomas and other tumors arising within nevus sebaceous. J Invest Dermatol. 2001;117:1666-1670.
  11. Levinsohn JL, Tian LC, Boyden LM, et al. Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceus [published online October 25, 2012]. J Invest Dermatol. 2013;133:827-830.
  12. Happle R. Nevus sebaceus is a mosaic RASopathy. J Invest Dermatol. 2013;133:597-600.
  13. Luo S, Tsao H. Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies. J Invest Dermatol. 2014;134:2493-2496.
  14. Mehregan AH, Pinkus H. Life history of organoid nevi. special reference to nevus sebaceus of Jadassohn. Arch Dermatol. 1965;91:574-588.
  15. Muñoz-Pérez MA, García-Hernandez MJ, Ríos JJ, et al. Sebaceus naevi: a clinicopathologic study. J Eur Acad Dermatol Venereol. 2002;16:319-324.
  16. Altaykan A, Ersoy-Evans S, Erkin G, et al. Basal cell carcinoma arising in nevus sebaceous during childhood. Pediatr Dermatol. 2008;25:616-619.
  17. Turner CD, Shea CR, Rosoff PM. Basal cell carcinoma originating from a nevus sebaceus on the scalp of a 7-year-old boy. J Pediatr Hematol Oncol. 2001;23:247-249.
  18. Jaqueti G, Requena L, Sánchez Yus E. Trichoblastoma is the most common neoplasm developed in nevus sebaceus of Jadassohn: a clinicopathologic study of a series of 155 cases. Am J Dermatopathol. 2000;22:108-118.
  19. Cribier B, Scrivener Y, Grosshans E. Tumors arising in nevus sebaceus: a study of 596 cases. J Am Acad Dermatol. 2000;42(2, pt 1):263-268.
  20. Paudel U, Jha A, Pokhrel DB, et al. Apocrine carcinoma developing in a naevus sebaceous of scalp. Kathmandu Univ Med J (KUMJ). 2012;10:103-105.
  21. Domingo J, Helwig EB. Malignant neoplasms associated with nevus sebaceus of Jadassohn. J Am Acad Dermatol. 1979;1:545-556.
  22. Tanese K, Wakabayashi A, Suzuki T, et al. Immunoexpression of human epidermal growth factor receptor-2 in apocrine carcinoma arising in naevus sebaceous, case report [published online August 23, 2009]. J Eur Acad Dermatol Venereol. 2010;24:360-362.
  23. Dalle S, Skowron F, Balme B, et al. Apocrine carcinoma developed in nevus sebaceus of Jadassohn. Eur J Dermatol. 2003;13:487-489.
  24. Jacyk WK, Requena L, Sánchez Yus E, et al. Tubular apocrine carcinoma arising in a nevus sebaceus of Jadassohn. Am J Dermatopathol. 1998;20:389-392.
  25. Ansai S, Koseki S, Hashimoto H, et al. A case of ductal sweat gland carcinoma connected to syringocystadenoma papilliferum arising in nevus sebaceus. J Cutan Pathol. 1994;21:557-563.
  26. Robson A, Lazar AJ, Ben Nagi J, et al. Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. Am J Surg Pathol. 2008;32:682-690.
  27. Paties C, Taccagni GL, Papotti M, et al. Apocrine carcinoma of the skin. a clinicopathologic, immunocytochemical, and ultrastructural study. Cancer. 1993;71:375-381.
  28. Davison SP, Khachemoune A, Yu D, et al. Nevus sebaceus of Jadassohn revisited with reconstruction options. Int J Dermatol. 2005;44:145-150.
  29. Chepla KJ, Gosain AK. Giant nevus sebaceus: definition, surgical techniques, and rationale for treatment. Plast Reconstr Surg. 2012;130:296E-304E.
  30. Kiedrowicz M, Kacalak-Rzepka A, Królicki A et al. Therapeutic effects of CO2 laser therapy of linear nevus sebaceous in the course of the Schimmelpenning-Feuerstein-Mims syndrome. Postepy Dermatol Allergol. 2013;30:320-323.
  31. Ashinoff R. Linear nevus sebaceus of Jadassohn treated with the carbon dioxide laser. Pediatr Dermatol. 1993;10:189-191.
  32. van de Warrenburg BP, van Gulik S, Renier WO, et al. The linear naevus sebaceus syndrome. Clin Neurol Neurosurg. 1998;100:126-132.
Article PDF
Author and Disclosure Information

From Nova Southeastern University College of Osteopathic Medicine/Largo Medical Center, Florida.

The authors report no conflict of interest.

Correspondence: Natalie Edgar, DO, Largo Medical Center, Graduate Medical Education, 201 14th St SW, Largo, FL 33770 (natalie.edgar@okstate.edu).

Issue
Cutis - 102(4)
Publications
Topics
Page Number
291-294
Sections
Author and Disclosure Information

From Nova Southeastern University College of Osteopathic Medicine/Largo Medical Center, Florida.

The authors report no conflict of interest.

Correspondence: Natalie Edgar, DO, Largo Medical Center, Graduate Medical Education, 201 14th St SW, Largo, FL 33770 (natalie.edgar@okstate.edu).

Author and Disclosure Information

From Nova Southeastern University College of Osteopathic Medicine/Largo Medical Center, Florida.

The authors report no conflict of interest.

Correspondence: Natalie Edgar, DO, Largo Medical Center, Graduate Medical Education, 201 14th St SW, Largo, FL 33770 (natalie.edgar@okstate.edu).

Article PDF
Article PDF

Nevus sebaceus (NS) is a benign hair follicle neoplasm present in approximately 1.3% of the population, typically involving the scalp, neck, or face.1 These lesions usually are present at birth or identified soon after, during the first year. They present as a yellowish hairless patch or plaque but can develop a more papillomatous appearance, especially after puberty. Historically, the concern with NS was its tendency to transform into basal cell carcinoma (BCC), which prompted surgical excision of the lesion during childhood. This theory has been discounted more recently, as further research has suggested that what was once thought to be BCC may have been confused with the similarly appearing trichoblastoma; however, malignant transformation of NS does still occur, with BCC still being the most common.2 We present the case of a long-standing NS with rare transformation to apocrine carcinoma.

Case Report

A 76-year-old woman presented with several new lesions within a previously diagnosed NS. She reported having the large plaque for as long as she could recall but reported that several new growths developed within the plaque over the last 2 months, slowly increasing in size. She reported a prior biopsy within the growth several years prior, which she described as an irritated seborrheic keratosis.

Physical examination demonstrated 4 distinct lesions within the flesh-colored, verrucous plaque located on the left side of the temporal scalp (Figure 1). The first lesion was a 2.5-cm pearly, pink, exophytic tumor (labeled as A in Figure 1). The next 2 lesions were brown, pedunculated, verrucous papules (labeled as B and C in Figure 1). The last lesion was a purple papule (labeled as D in Figure 1). Four shave biopsies were performed for histologic analysis of the lesions. Lesions B, C, and D were consistent with trichoblastomas, as pathology showed basaloid epithelial tumors that displayed primitive follicular structures, areas of stromal induction, and some pigmentation. Lesion A, originally thought to be suspicious for a BCC, was determined to be a primary cutaneous apocrine adenocarcinoma upon pathologic review. The pathology showed a dermal tumor displaying solid and tubular areas with decapitation secretion. Nuclear pleomorphism and mitoses were present (Figure 2), and staining for carcinoembryonic antigen was positive (Figure 3). Immunoreactivity with epithelial membrane antigen and cytokeratin 7 was noted as well as focal positivity for mammaglobin. Primary apocrine carcinoma was favored over metastatic carcinoma due to the location of the lesion within an NS along with a negative history of internal malignancy. Dermatopathology recommended complete removal of all lesions within the NS.

Figure1
Figure 1. Verrucous plaque and 4 distinct neoplasms (labeled A–D) on the left side of the temporal scalp.

Figure2
Figure 2. Apocrine carcinoma histopathology demonstrating solid and tubular areas with decapitation secretion (A)(H&E). On high power, marked nuclear pleomorphism and increased mitotic activity were observed (B)(H&E).

Figure3
Figure 3. Apocrine carcinoma demonstrating carcinoembryonic antigen staining positivity.


Upon discussing biopsy results and recommendations with our patient, she agreed to undergo excision with intraoperative pathology by a plastic surgeon within our practice to ensure clear margins. The surgical defect following excision was sizeable and closed utilizing a rhomboid flap, full-thickness skin graft, and a split-thickness skin graft. At surgical follow-up, she was doing well and there have been no signs of local recurrence for 10 months since excision.

 

 

Comment

Presentation
Nevus sebaceus is the most common adnexal tumor and is classified as a benign congenital hair follicle tumor that is located most commonly on the scalp but also occurs on the face and neck.1 The lesions usually are present at birth but also can develop during the first year of life.2 Diagnosis may be later, during adolescence, when patients seek medical attention during the lesion’s rapid growth phase.1 Nevus sebaceus also is known as an organoid nevus because it may contain all components of the skin. It was originally identified by Jadassohn in 1895.3 It presents as a yellowish, smooth, hairless patch or plaque in prepubertal patients. During adolescence, the lesion typically becomes more yellowish, as well as papillomatous, scaly, or warty. The reported incidence of NS is 0.05% to 1% in dermatology patients.2

Differential
Nevus sebaceus also is a component of several syndromes that should be kept in mind, including Schimmelpenning-Feuerstein-Mims syndrome, which presents with neurologic, skeletal, genitourinary, cardiovascular, and ophthalmic disorders, in addition to cutaneous features. Others include phacomatosis pigmentokeratotica, didmyosis aplasticosebacea, SCALP syndrome (sebaceus nevus, central nervous system malformations, aplasia cutis congenita, limbal dermoid, and pigmented nevus), and more.4,5

Etiology
The etiology of NS has not been completely determined. One study that evaluated 44 NS tissue samples suggested the presence of human papillomavirus (HPV) in NS formation, finding that 82% of NS lesions studied contained HPV DNA. From these results, Carlson et al6 suggested a possible maternal transmission of HPV and infection of ectodermal cells as a potential cause of NS; however, this hypothesis was soon challenged by a study that showed a complete absence of HPV in 16 samples via histological evaluation and polymerase chain reaction for a broad range of HPV types.7 There were investigations into a patched (PTCH) deletion as the cause of NS and thus explained the historically high rate of secondary BCC.8 Further studies showed no mutations at the PTCH locus in trichoblastomas or other tumors arising from NS.9,10

More recent studies have recognized HRAS and KRAS mutations as a causative factor in NS.11 Nevus sebaceus belongs to a group of syndromes resulting from lethal mutations that survive via mosaicism. Nevus sebaceus is caused by postzygotic HRAS or KRAS mutations and is known as a mosaic RASopathy.12 In fact, there is growing evidence to suggest that other nevoid proliferations including keratinocytic epidermal nevi and melanocytic nevi also fall into the spectrum of mosaic RASopathies.13

Staging
There are 3 clinical stages of NS, originally described by Mehregan and Pinkus.14 In stage I (historically known as the infantile stage), the lesion presents as a yellow to pink, smooth, hairless patch. Histologic features include immature hair follicles and hypoplastic sebaceous glands. In stage II (also known as the puberty stage), the lesion becomes more pronounced. Firmer plaques can develop with hyperkeratosis. Hormonal changes cause sebaceous glands to develop, accompanied by epidermal hyperplasia and maturation of apocrine glands. Stage III (the tumoral stage) is a period that various neoplasms have the highest likelihood of occurring. Nevus sebaceus in an adolescent or adult demonstrates mature adnexal structures and greater epidermal hyperplasia.2,4,15

Malignancy
By virtue of these stages of NS development, malignant transformation is expected most often during stage III. However, cases have been reported of malignant tumor development in NS in children before puberty. Two case reports described a 7-year-old boy and a 10-year-old boy diagnosed with a BCC arising from an NS.16,17 However, secondary BCC formation before 16 years of age is rare. Basal cell carcinoma arising from an NS has been commonly reported and is the most common malignant neoplasm in NS (1.1%).2,3 However, the most common neoplasm overall is trichoblastoma (7.4%). The second most common tumor was syringocystadenoma papilliferum, occurring in approximately 5.2% of NS cases. The neoplasm rate in NS was found to be proportional to the patient age.2,18 Multiple studies have shown the overall rate of secondary neoplasms in NS to be 13% to 21.4%, with malignant tumors composing 0.8% to 2.5%.2,15,19 Other neoplasms that have been reported include keratoacanthoma, trichilemmoma, sebaceoma, nevocellular nevus, squamous cell carcinoma, adnexal carcinoma, apocrine adenocarcinoma, and malignant melanoma.19-21

It is argued that the reported rate of BCC formation is overestimated, as prior studies incorrectly labeled trichoblastomas as BCCs. In fact, the largest studies of NS from the 1990s revealed lower rates of malignant secondary tumors than previously determined.4

The identification of apocrine adenocarcinoma tumors arising from NS is exceedingly rare. A study performed by Cribier et al19 in 2000 retrospectively analyzed 596 cases of excised NS from 1932 to 1998. No apocrine carcinomas were reported in this study.19 Approximately 12 cases have been previously reported throughout the literature.20-26 Apocrine carcinomas occur most frequently in apocrine-rich areas such as the axillae, external ears, eyelids, and anogenital area. However, in the cases with apocrine carcinomas that developed from NS, the carcinomas have been located almost exclusively on the scalp.23

Histopathology
Histopathologic examination reveals considerable variation in morphology, and an underlying pattern has been difficult to recognize. Unfortunately, some authors have concluded that the diagnosis of apocrine carcinoma is relatively subjective.26 Robson et al26 identified 3 general architectural patterns: tubular, tubulopapillary, and solid. Tubular structures consisted of glands and ducts lined by a single or multilayered epithelium. Tubulopapillary architecture was characterized by epithelium forming papillary folds without a fibrovascular core. The solid morphology showed sheets of cells with limited ductal or tubular formation.26 The most specific criteria of these apocrine carcinomas are identification of decapitation secretion, periodic acid–Schiff–positive diastase-resistant material present in the cells or lumen, and positive immunostaining for gross cystic disease fluid protein-15.27

Robson et al26 reported estrogen receptor positivity and androgen receptor positivity in 62% and 64% of 24 primary apocrine carcinoma cases, respectively. However, whether these markers are as common in NS-related apocrine carcinomas has yet to be noted in the literature. One study reports a case of apocrine carcinoma from NS with positive staining for human epidermal growth factor-2, a cell membrane receptor tyrosine kinase commonly investigated in breast cancers and extramammary Paget disease.22

These apocrine carcinomas do have the potential for lymphatic metastasis, as seen with multiple studies. Domingo and Helwig21 identified regional lymph node metastasis in 2 of its 4 apocrine carcinoma patients. Robson et al26 reported lymphovascular invasion in 4 cases and perineural invasion in 2 of 24 patients studied. However, even in the context of recurrence and regional metastasis, the prognosis was good and seldom fatal.26

Treatment
The most effective treatment of NS is excision of dermal and epidermal components. Excision should be completed with a minimum of 2- to 3-mm margins and full thickness down to the underlying supporting fat.28 Historically, the practice of prophylactic excision of NS was supported by the potential for malignant transformation; however, early excision of NS may be less reasonable in light of these more recent studies showing lower incidence of BCC (0.8%), replaced by benign trichoblastomas.19 In the case of apocrine carcinoma development, excision is undoubtedly recommended, with unclear recommendations regarding further evaluation for metastasis.

Excision also may be favored for cosmetic purposes, given the visible regions where NS tends to develop. Chepla and Gosain29 argued that surgical intervention should be based on other factors such as location on the scalp, alopecia, and other issues affecting appearance and monitoring rather than incidence of malignant transformation. Close monitoring and biopsy of suspicious areas is a more conservative option.

Other therapies include CO2 laser, as demonstrated by Kiedrowicz et al,30 on linear NS in a patient with Schimmelpenning-Feuerstein-Mims syndrome.31 However, this approach is palliative and not effective in removing the entire lesion. Electrodesiccation and curettage and dermabrasion also are not good options for the same reason.4

Occurrence in Children
Nevus sebaceus in children, accompanied by other findings suggestive of epidermal nevus syndromes, should prompt further investigation. Schimmelpenning-Feuerstein-Mims syndrome includes major neurological abnormalities including hemimegalencephaly and seizures.32

Conclusion

Apocrine carcinomas are malignant neoplasms that may rarely arise within an NS. Their clinical identification is difficult and requires histopathologic evaluation. Upon recognition, prompt excision with tumor-free margins is recommended. As a rare entity, little data is available regarding its metastatic potential or overall survival rates. Further investigation is clearly necessary as new cases arise.

Nevus sebaceus (NS) is a benign hair follicle neoplasm present in approximately 1.3% of the population, typically involving the scalp, neck, or face.1 These lesions usually are present at birth or identified soon after, during the first year. They present as a yellowish hairless patch or plaque but can develop a more papillomatous appearance, especially after puberty. Historically, the concern with NS was its tendency to transform into basal cell carcinoma (BCC), which prompted surgical excision of the lesion during childhood. This theory has been discounted more recently, as further research has suggested that what was once thought to be BCC may have been confused with the similarly appearing trichoblastoma; however, malignant transformation of NS does still occur, with BCC still being the most common.2 We present the case of a long-standing NS with rare transformation to apocrine carcinoma.

Case Report

A 76-year-old woman presented with several new lesions within a previously diagnosed NS. She reported having the large plaque for as long as she could recall but reported that several new growths developed within the plaque over the last 2 months, slowly increasing in size. She reported a prior biopsy within the growth several years prior, which she described as an irritated seborrheic keratosis.

Physical examination demonstrated 4 distinct lesions within the flesh-colored, verrucous plaque located on the left side of the temporal scalp (Figure 1). The first lesion was a 2.5-cm pearly, pink, exophytic tumor (labeled as A in Figure 1). The next 2 lesions were brown, pedunculated, verrucous papules (labeled as B and C in Figure 1). The last lesion was a purple papule (labeled as D in Figure 1). Four shave biopsies were performed for histologic analysis of the lesions. Lesions B, C, and D were consistent with trichoblastomas, as pathology showed basaloid epithelial tumors that displayed primitive follicular structures, areas of stromal induction, and some pigmentation. Lesion A, originally thought to be suspicious for a BCC, was determined to be a primary cutaneous apocrine adenocarcinoma upon pathologic review. The pathology showed a dermal tumor displaying solid and tubular areas with decapitation secretion. Nuclear pleomorphism and mitoses were present (Figure 2), and staining for carcinoembryonic antigen was positive (Figure 3). Immunoreactivity with epithelial membrane antigen and cytokeratin 7 was noted as well as focal positivity for mammaglobin. Primary apocrine carcinoma was favored over metastatic carcinoma due to the location of the lesion within an NS along with a negative history of internal malignancy. Dermatopathology recommended complete removal of all lesions within the NS.

Figure1
Figure 1. Verrucous plaque and 4 distinct neoplasms (labeled A–D) on the left side of the temporal scalp.

Figure2
Figure 2. Apocrine carcinoma histopathology demonstrating solid and tubular areas with decapitation secretion (A)(H&E). On high power, marked nuclear pleomorphism and increased mitotic activity were observed (B)(H&E).

Figure3
Figure 3. Apocrine carcinoma demonstrating carcinoembryonic antigen staining positivity.


Upon discussing biopsy results and recommendations with our patient, she agreed to undergo excision with intraoperative pathology by a plastic surgeon within our practice to ensure clear margins. The surgical defect following excision was sizeable and closed utilizing a rhomboid flap, full-thickness skin graft, and a split-thickness skin graft. At surgical follow-up, she was doing well and there have been no signs of local recurrence for 10 months since excision.

 

 

Comment

Presentation
Nevus sebaceus is the most common adnexal tumor and is classified as a benign congenital hair follicle tumor that is located most commonly on the scalp but also occurs on the face and neck.1 The lesions usually are present at birth but also can develop during the first year of life.2 Diagnosis may be later, during adolescence, when patients seek medical attention during the lesion’s rapid growth phase.1 Nevus sebaceus also is known as an organoid nevus because it may contain all components of the skin. It was originally identified by Jadassohn in 1895.3 It presents as a yellowish, smooth, hairless patch or plaque in prepubertal patients. During adolescence, the lesion typically becomes more yellowish, as well as papillomatous, scaly, or warty. The reported incidence of NS is 0.05% to 1% in dermatology patients.2

Differential
Nevus sebaceus also is a component of several syndromes that should be kept in mind, including Schimmelpenning-Feuerstein-Mims syndrome, which presents with neurologic, skeletal, genitourinary, cardiovascular, and ophthalmic disorders, in addition to cutaneous features. Others include phacomatosis pigmentokeratotica, didmyosis aplasticosebacea, SCALP syndrome (sebaceus nevus, central nervous system malformations, aplasia cutis congenita, limbal dermoid, and pigmented nevus), and more.4,5

Etiology
The etiology of NS has not been completely determined. One study that evaluated 44 NS tissue samples suggested the presence of human papillomavirus (HPV) in NS formation, finding that 82% of NS lesions studied contained HPV DNA. From these results, Carlson et al6 suggested a possible maternal transmission of HPV and infection of ectodermal cells as a potential cause of NS; however, this hypothesis was soon challenged by a study that showed a complete absence of HPV in 16 samples via histological evaluation and polymerase chain reaction for a broad range of HPV types.7 There were investigations into a patched (PTCH) deletion as the cause of NS and thus explained the historically high rate of secondary BCC.8 Further studies showed no mutations at the PTCH locus in trichoblastomas or other tumors arising from NS.9,10

More recent studies have recognized HRAS and KRAS mutations as a causative factor in NS.11 Nevus sebaceus belongs to a group of syndromes resulting from lethal mutations that survive via mosaicism. Nevus sebaceus is caused by postzygotic HRAS or KRAS mutations and is known as a mosaic RASopathy.12 In fact, there is growing evidence to suggest that other nevoid proliferations including keratinocytic epidermal nevi and melanocytic nevi also fall into the spectrum of mosaic RASopathies.13

Staging
There are 3 clinical stages of NS, originally described by Mehregan and Pinkus.14 In stage I (historically known as the infantile stage), the lesion presents as a yellow to pink, smooth, hairless patch. Histologic features include immature hair follicles and hypoplastic sebaceous glands. In stage II (also known as the puberty stage), the lesion becomes more pronounced. Firmer plaques can develop with hyperkeratosis. Hormonal changes cause sebaceous glands to develop, accompanied by epidermal hyperplasia and maturation of apocrine glands. Stage III (the tumoral stage) is a period that various neoplasms have the highest likelihood of occurring. Nevus sebaceus in an adolescent or adult demonstrates mature adnexal structures and greater epidermal hyperplasia.2,4,15

Malignancy
By virtue of these stages of NS development, malignant transformation is expected most often during stage III. However, cases have been reported of malignant tumor development in NS in children before puberty. Two case reports described a 7-year-old boy and a 10-year-old boy diagnosed with a BCC arising from an NS.16,17 However, secondary BCC formation before 16 years of age is rare. Basal cell carcinoma arising from an NS has been commonly reported and is the most common malignant neoplasm in NS (1.1%).2,3 However, the most common neoplasm overall is trichoblastoma (7.4%). The second most common tumor was syringocystadenoma papilliferum, occurring in approximately 5.2% of NS cases. The neoplasm rate in NS was found to be proportional to the patient age.2,18 Multiple studies have shown the overall rate of secondary neoplasms in NS to be 13% to 21.4%, with malignant tumors composing 0.8% to 2.5%.2,15,19 Other neoplasms that have been reported include keratoacanthoma, trichilemmoma, sebaceoma, nevocellular nevus, squamous cell carcinoma, adnexal carcinoma, apocrine adenocarcinoma, and malignant melanoma.19-21

It is argued that the reported rate of BCC formation is overestimated, as prior studies incorrectly labeled trichoblastomas as BCCs. In fact, the largest studies of NS from the 1990s revealed lower rates of malignant secondary tumors than previously determined.4

The identification of apocrine adenocarcinoma tumors arising from NS is exceedingly rare. A study performed by Cribier et al19 in 2000 retrospectively analyzed 596 cases of excised NS from 1932 to 1998. No apocrine carcinomas were reported in this study.19 Approximately 12 cases have been previously reported throughout the literature.20-26 Apocrine carcinomas occur most frequently in apocrine-rich areas such as the axillae, external ears, eyelids, and anogenital area. However, in the cases with apocrine carcinomas that developed from NS, the carcinomas have been located almost exclusively on the scalp.23

Histopathology
Histopathologic examination reveals considerable variation in morphology, and an underlying pattern has been difficult to recognize. Unfortunately, some authors have concluded that the diagnosis of apocrine carcinoma is relatively subjective.26 Robson et al26 identified 3 general architectural patterns: tubular, tubulopapillary, and solid. Tubular structures consisted of glands and ducts lined by a single or multilayered epithelium. Tubulopapillary architecture was characterized by epithelium forming papillary folds without a fibrovascular core. The solid morphology showed sheets of cells with limited ductal or tubular formation.26 The most specific criteria of these apocrine carcinomas are identification of decapitation secretion, periodic acid–Schiff–positive diastase-resistant material present in the cells or lumen, and positive immunostaining for gross cystic disease fluid protein-15.27

Robson et al26 reported estrogen receptor positivity and androgen receptor positivity in 62% and 64% of 24 primary apocrine carcinoma cases, respectively. However, whether these markers are as common in NS-related apocrine carcinomas has yet to be noted in the literature. One study reports a case of apocrine carcinoma from NS with positive staining for human epidermal growth factor-2, a cell membrane receptor tyrosine kinase commonly investigated in breast cancers and extramammary Paget disease.22

These apocrine carcinomas do have the potential for lymphatic metastasis, as seen with multiple studies. Domingo and Helwig21 identified regional lymph node metastasis in 2 of its 4 apocrine carcinoma patients. Robson et al26 reported lymphovascular invasion in 4 cases and perineural invasion in 2 of 24 patients studied. However, even in the context of recurrence and regional metastasis, the prognosis was good and seldom fatal.26

Treatment
The most effective treatment of NS is excision of dermal and epidermal components. Excision should be completed with a minimum of 2- to 3-mm margins and full thickness down to the underlying supporting fat.28 Historically, the practice of prophylactic excision of NS was supported by the potential for malignant transformation; however, early excision of NS may be less reasonable in light of these more recent studies showing lower incidence of BCC (0.8%), replaced by benign trichoblastomas.19 In the case of apocrine carcinoma development, excision is undoubtedly recommended, with unclear recommendations regarding further evaluation for metastasis.

Excision also may be favored for cosmetic purposes, given the visible regions where NS tends to develop. Chepla and Gosain29 argued that surgical intervention should be based on other factors such as location on the scalp, alopecia, and other issues affecting appearance and monitoring rather than incidence of malignant transformation. Close monitoring and biopsy of suspicious areas is a more conservative option.

Other therapies include CO2 laser, as demonstrated by Kiedrowicz et al,30 on linear NS in a patient with Schimmelpenning-Feuerstein-Mims syndrome.31 However, this approach is palliative and not effective in removing the entire lesion. Electrodesiccation and curettage and dermabrasion also are not good options for the same reason.4

Occurrence in Children
Nevus sebaceus in children, accompanied by other findings suggestive of epidermal nevus syndromes, should prompt further investigation. Schimmelpenning-Feuerstein-Mims syndrome includes major neurological abnormalities including hemimegalencephaly and seizures.32

Conclusion

Apocrine carcinomas are malignant neoplasms that may rarely arise within an NS. Their clinical identification is difficult and requires histopathologic evaluation. Upon recognition, prompt excision with tumor-free margins is recommended. As a rare entity, little data is available regarding its metastatic potential or overall survival rates. Further investigation is clearly necessary as new cases arise.

References
  1. Kamyab-Hesari K, Balochi K, Afshar N, et al. Clinicopathological study of 1016 consecutive adnexal skin tumors. Acta Med Iran. 2013;51:879-885.
  2. Idriss MH, Elston DM. Secondary neoplasms associated with nevus sebaceus of Jadassohn: a study of 707 cases. J Am Acad Dermatol. 2014;70:332-337.
  3. Ball EA, Hussain M, Moss AL. Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol. 2005;30:259-260.
  4. Moody MN, Landau JM, Goldberg LH. Nevus sebaceous revisited. Pediatr Dermatol. 2012;29:15-23.
  5. Happle R. The group of epidermal nevus syndromes part I. well defined phenotypes. J Am Acad Dermatol. 2010;63:1-22; quiz 23-24.
  6. Carlson JA, Cribier B, Nuovo G, et al. Epidermodysplasia verruciformis-associated and genital-mucosal high-risk human papillomavirus DNA are prevalent in nevus sebaceus of Jadassohn. J Am Acad Dermatol. 2008;59:279-294.
  7. Kim D, Benjamin LT, Sahoo MK, et al. Human papilloma virus is not prevalent in nevus sebaceus [published online November 14, 2013]. Pediatr Dermatol. 2014;31:326-330.
  8. Xin H, Matt D, Qin JZ, et al. The sebaceous nevus: a nevus with deletions of the PTCH gene. Cancer Res. 1999;59:1834-1836.
  9. Hafner C, Schmiemann V, Ruetten A, et al. PTCH mutations are not mainly involved in the pathogenesis of sporadic trichoblastomas. Hum Pathol. 2007;38:1496-1500.
  10. Takata M, Tojo M, Hatta N, et al. No evidence of deregulated patched-hedgehog signaling pathway in trichoblastomas and other tumors arising within nevus sebaceous. J Invest Dermatol. 2001;117:1666-1670.
  11. Levinsohn JL, Tian LC, Boyden LM, et al. Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceus [published online October 25, 2012]. J Invest Dermatol. 2013;133:827-830.
  12. Happle R. Nevus sebaceus is a mosaic RASopathy. J Invest Dermatol. 2013;133:597-600.
  13. Luo S, Tsao H. Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies. J Invest Dermatol. 2014;134:2493-2496.
  14. Mehregan AH, Pinkus H. Life history of organoid nevi. special reference to nevus sebaceus of Jadassohn. Arch Dermatol. 1965;91:574-588.
  15. Muñoz-Pérez MA, García-Hernandez MJ, Ríos JJ, et al. Sebaceus naevi: a clinicopathologic study. J Eur Acad Dermatol Venereol. 2002;16:319-324.
  16. Altaykan A, Ersoy-Evans S, Erkin G, et al. Basal cell carcinoma arising in nevus sebaceous during childhood. Pediatr Dermatol. 2008;25:616-619.
  17. Turner CD, Shea CR, Rosoff PM. Basal cell carcinoma originating from a nevus sebaceus on the scalp of a 7-year-old boy. J Pediatr Hematol Oncol. 2001;23:247-249.
  18. Jaqueti G, Requena L, Sánchez Yus E. Trichoblastoma is the most common neoplasm developed in nevus sebaceus of Jadassohn: a clinicopathologic study of a series of 155 cases. Am J Dermatopathol. 2000;22:108-118.
  19. Cribier B, Scrivener Y, Grosshans E. Tumors arising in nevus sebaceus: a study of 596 cases. J Am Acad Dermatol. 2000;42(2, pt 1):263-268.
  20. Paudel U, Jha A, Pokhrel DB, et al. Apocrine carcinoma developing in a naevus sebaceous of scalp. Kathmandu Univ Med J (KUMJ). 2012;10:103-105.
  21. Domingo J, Helwig EB. Malignant neoplasms associated with nevus sebaceus of Jadassohn. J Am Acad Dermatol. 1979;1:545-556.
  22. Tanese K, Wakabayashi A, Suzuki T, et al. Immunoexpression of human epidermal growth factor receptor-2 in apocrine carcinoma arising in naevus sebaceous, case report [published online August 23, 2009]. J Eur Acad Dermatol Venereol. 2010;24:360-362.
  23. Dalle S, Skowron F, Balme B, et al. Apocrine carcinoma developed in nevus sebaceus of Jadassohn. Eur J Dermatol. 2003;13:487-489.
  24. Jacyk WK, Requena L, Sánchez Yus E, et al. Tubular apocrine carcinoma arising in a nevus sebaceus of Jadassohn. Am J Dermatopathol. 1998;20:389-392.
  25. Ansai S, Koseki S, Hashimoto H, et al. A case of ductal sweat gland carcinoma connected to syringocystadenoma papilliferum arising in nevus sebaceus. J Cutan Pathol. 1994;21:557-563.
  26. Robson A, Lazar AJ, Ben Nagi J, et al. Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. Am J Surg Pathol. 2008;32:682-690.
  27. Paties C, Taccagni GL, Papotti M, et al. Apocrine carcinoma of the skin. a clinicopathologic, immunocytochemical, and ultrastructural study. Cancer. 1993;71:375-381.
  28. Davison SP, Khachemoune A, Yu D, et al. Nevus sebaceus of Jadassohn revisited with reconstruction options. Int J Dermatol. 2005;44:145-150.
  29. Chepla KJ, Gosain AK. Giant nevus sebaceus: definition, surgical techniques, and rationale for treatment. Plast Reconstr Surg. 2012;130:296E-304E.
  30. Kiedrowicz M, Kacalak-Rzepka A, Królicki A et al. Therapeutic effects of CO2 laser therapy of linear nevus sebaceous in the course of the Schimmelpenning-Feuerstein-Mims syndrome. Postepy Dermatol Allergol. 2013;30:320-323.
  31. Ashinoff R. Linear nevus sebaceus of Jadassohn treated with the carbon dioxide laser. Pediatr Dermatol. 1993;10:189-191.
  32. van de Warrenburg BP, van Gulik S, Renier WO, et al. The linear naevus sebaceus syndrome. Clin Neurol Neurosurg. 1998;100:126-132.
References
  1. Kamyab-Hesari K, Balochi K, Afshar N, et al. Clinicopathological study of 1016 consecutive adnexal skin tumors. Acta Med Iran. 2013;51:879-885.
  2. Idriss MH, Elston DM. Secondary neoplasms associated with nevus sebaceus of Jadassohn: a study of 707 cases. J Am Acad Dermatol. 2014;70:332-337.
  3. Ball EA, Hussain M, Moss AL. Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol. 2005;30:259-260.
  4. Moody MN, Landau JM, Goldberg LH. Nevus sebaceous revisited. Pediatr Dermatol. 2012;29:15-23.
  5. Happle R. The group of epidermal nevus syndromes part I. well defined phenotypes. J Am Acad Dermatol. 2010;63:1-22; quiz 23-24.
  6. Carlson JA, Cribier B, Nuovo G, et al. Epidermodysplasia verruciformis-associated and genital-mucosal high-risk human papillomavirus DNA are prevalent in nevus sebaceus of Jadassohn. J Am Acad Dermatol. 2008;59:279-294.
  7. Kim D, Benjamin LT, Sahoo MK, et al. Human papilloma virus is not prevalent in nevus sebaceus [published online November 14, 2013]. Pediatr Dermatol. 2014;31:326-330.
  8. Xin H, Matt D, Qin JZ, et al. The sebaceous nevus: a nevus with deletions of the PTCH gene. Cancer Res. 1999;59:1834-1836.
  9. Hafner C, Schmiemann V, Ruetten A, et al. PTCH mutations are not mainly involved in the pathogenesis of sporadic trichoblastomas. Hum Pathol. 2007;38:1496-1500.
  10. Takata M, Tojo M, Hatta N, et al. No evidence of deregulated patched-hedgehog signaling pathway in trichoblastomas and other tumors arising within nevus sebaceous. J Invest Dermatol. 2001;117:1666-1670.
  11. Levinsohn JL, Tian LC, Boyden LM, et al. Whole-exome sequencing reveals somatic mutations in HRAS and KRAS, which cause nevus sebaceus [published online October 25, 2012]. J Invest Dermatol. 2013;133:827-830.
  12. Happle R. Nevus sebaceus is a mosaic RASopathy. J Invest Dermatol. 2013;133:597-600.
  13. Luo S, Tsao H. Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies. J Invest Dermatol. 2014;134:2493-2496.
  14. Mehregan AH, Pinkus H. Life history of organoid nevi. special reference to nevus sebaceus of Jadassohn. Arch Dermatol. 1965;91:574-588.
  15. Muñoz-Pérez MA, García-Hernandez MJ, Ríos JJ, et al. Sebaceus naevi: a clinicopathologic study. J Eur Acad Dermatol Venereol. 2002;16:319-324.
  16. Altaykan A, Ersoy-Evans S, Erkin G, et al. Basal cell carcinoma arising in nevus sebaceous during childhood. Pediatr Dermatol. 2008;25:616-619.
  17. Turner CD, Shea CR, Rosoff PM. Basal cell carcinoma originating from a nevus sebaceus on the scalp of a 7-year-old boy. J Pediatr Hematol Oncol. 2001;23:247-249.
  18. Jaqueti G, Requena L, Sánchez Yus E. Trichoblastoma is the most common neoplasm developed in nevus sebaceus of Jadassohn: a clinicopathologic study of a series of 155 cases. Am J Dermatopathol. 2000;22:108-118.
  19. Cribier B, Scrivener Y, Grosshans E. Tumors arising in nevus sebaceus: a study of 596 cases. J Am Acad Dermatol. 2000;42(2, pt 1):263-268.
  20. Paudel U, Jha A, Pokhrel DB, et al. Apocrine carcinoma developing in a naevus sebaceous of scalp. Kathmandu Univ Med J (KUMJ). 2012;10:103-105.
  21. Domingo J, Helwig EB. Malignant neoplasms associated with nevus sebaceus of Jadassohn. J Am Acad Dermatol. 1979;1:545-556.
  22. Tanese K, Wakabayashi A, Suzuki T, et al. Immunoexpression of human epidermal growth factor receptor-2 in apocrine carcinoma arising in naevus sebaceous, case report [published online August 23, 2009]. J Eur Acad Dermatol Venereol. 2010;24:360-362.
  23. Dalle S, Skowron F, Balme B, et al. Apocrine carcinoma developed in nevus sebaceus of Jadassohn. Eur J Dermatol. 2003;13:487-489.
  24. Jacyk WK, Requena L, Sánchez Yus E, et al. Tubular apocrine carcinoma arising in a nevus sebaceus of Jadassohn. Am J Dermatopathol. 1998;20:389-392.
  25. Ansai S, Koseki S, Hashimoto H, et al. A case of ductal sweat gland carcinoma connected to syringocystadenoma papilliferum arising in nevus sebaceus. J Cutan Pathol. 1994;21:557-563.
  26. Robson A, Lazar AJ, Ben Nagi J, et al. Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. Am J Surg Pathol. 2008;32:682-690.
  27. Paties C, Taccagni GL, Papotti M, et al. Apocrine carcinoma of the skin. a clinicopathologic, immunocytochemical, and ultrastructural study. Cancer. 1993;71:375-381.
  28. Davison SP, Khachemoune A, Yu D, et al. Nevus sebaceus of Jadassohn revisited with reconstruction options. Int J Dermatol. 2005;44:145-150.
  29. Chepla KJ, Gosain AK. Giant nevus sebaceus: definition, surgical techniques, and rationale for treatment. Plast Reconstr Surg. 2012;130:296E-304E.
  30. Kiedrowicz M, Kacalak-Rzepka A, Królicki A et al. Therapeutic effects of CO2 laser therapy of linear nevus sebaceous in the course of the Schimmelpenning-Feuerstein-Mims syndrome. Postepy Dermatol Allergol. 2013;30:320-323.
  31. Ashinoff R. Linear nevus sebaceus of Jadassohn treated with the carbon dioxide laser. Pediatr Dermatol. 1993;10:189-191.
  32. van de Warrenburg BP, van Gulik S, Renier WO, et al. The linear naevus sebaceus syndrome. Clin Neurol Neurosurg. 1998;100:126-132.
Issue
Cutis - 102(4)
Issue
Cutis - 102(4)
Page Number
291-294
Page Number
291-294
Publications
Publications
Topics
Article Type
Sections
Inside the Article

Practice Points

  • Nevus sebaceus (NS) in the centrofacial region has been correlated with a higher risk for neurological abnormalities, including intellectual disability and seizures.
  • Historically, basal cell carcinomas (BCCs) were considered a common occurrence arising from an NS, prompting prophylactic surgical excision of such lesions.
  • More recently, it has been recognized that the most common tumor to arise from NS is trichoblastoma rather than BCC; in fact, BCC and other malignancies have been found to be relatively rare compared to their benign counterparts.
  • In light of this discovery, observation of NS may be a more prudent course of treatment versus prophylactic surgical excision.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Article PDF Media